These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
334 related items for PubMed ID: 9535414
1. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414 [Abstract] [Full Text] [Related]
2. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Chen Z, Tan F, Erdös EG, Deddish PA. Hypertension; 2005 Dec; 46(6):1368-73. PubMed ID: 16246972 [Abstract] [Full Text] [Related]
3. Enhancement of bradykinin and resensitization of its B2 receptor. Marcic B, Deddish PA, Jackman HL, Erdös EG. Hypertension; 1999 Mar; 33(3):835-43. PubMed ID: 10082496 [Abstract] [Full Text] [Related]
4. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Tom B, de Vries R, Saxena PR, Danser AH. Hypertension; 2001 Jul; 38(1):95-9. PubMed ID: 11463767 [Abstract] [Full Text] [Related]
5. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. van Esch JH, Tom B, Dive V, Batenburg WW, Georgiadis D, Yiotakis A, van Gool JM, de Bruijn RJ, de Vries R, Danser AH. Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077 [Abstract] [Full Text] [Related]
6. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG. Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459 [Abstract] [Full Text] [Related]
8. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. Erdös EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. J Mol Cell Cardiol; 2002 Dec; 34(12):1569-76. PubMed ID: 12505055 [Abstract] [Full Text] [Related]
9. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Biochem J; 2004 Oct 01; 383(Pt 1):45-51. PubMed ID: 15283675 [Abstract] [Full Text] [Related]
10. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Circ Res; 2003 Jul 25; 93(2):148-54. PubMed ID: 12805239 [Abstract] [Full Text] [Related]
11. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Hypertension; 1998 Jan 25; 31(1 Pt 2):362-7. PubMed ID: 9453329 [Abstract] [Full Text] [Related]
12. Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor. Deddish PA, Marcic BM, Tan F, Jackman HL, Chen Z, Erdös EG. Hypertension; 2002 Feb 25; 39(2 Pt 2):619-23. PubMed ID: 11882619 [Abstract] [Full Text] [Related]
18. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdös EG. Hypertension; 2002 May 25; 39(5):976-81. PubMed ID: 12019279 [Abstract] [Full Text] [Related]